Mabxience S.A., headquartered in Switzerland, is a prominent player in the biopharmaceutical industry, specialising in the development and manufacturing of biosimilars and innovative biologics. Founded in 2015, the company has rapidly established itself in key operational regions across Europe and Latin America, focusing on enhancing patient access to high-quality therapies. Mabxience's core offerings include a range of biosimilars that are distinguished by their rigorous quality standards and commitment to affordability. The company has achieved significant milestones, including successful product launches and partnerships that bolster its market position. With a dedication to research and development, Mabxience continues to contribute to the evolving landscape of biopharmaceuticals, ensuring that patients receive effective and accessible treatment options.
How does Mabxience S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Mabxience S.A.'s score of 49 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Mabxience S.A., headquartered in Switzerland (CH), currently does not have specific carbon emissions data available for recent years, as indicated by the absence of emissions figures. The company is a current subsidiary of Insud Pharma S.L.U., which may influence its climate commitments and performance metrics. As of now, Mabxience S.A. has not established any documented reduction targets or climate pledges, nor does it report any initiatives under the Science Based Targets initiative (SBTi) or other climate frameworks. This lack of specific data suggests that the company may still be in the early stages of developing its climate strategy or reporting practices. Given the absence of direct emissions data and reduction initiatives, it is essential for Mabxience S.A. to consider setting measurable targets and engaging in climate action to align with industry standards and expectations. This would not only enhance their sustainability profile but also contribute positively to global climate efforts.
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 521,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 1,013,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 |
Mabxience S.A.'s Scope 3 emissions, which increased by 1% last year and increased by approximately 1% since 2023, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 44% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mabxience S.A. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.